RxDoctor Payments Data

Saberio Lo Presti Vega, MD

Cardiovascular Disease · Cleveland, OHNPI 1922402270

Payments from drug & device makers

$2,894in general payments, 2019–2025

Across 92 payments — averaging $31.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Heartflow, Inc.$788
  • Abbott$623
  • Amgen$360
  • Pfizer$175
  • AstraZeneca$167
  • Johnson & Johnson$162
  • plus $619 from 7 others

What the payments were for

  • Consulting fees$78827%
  • Food & beverage$2,10773%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,894 in reported general payments places this provider in the 55th percentile of 827 cardiovascular disease providers in Ohio.

See all cardiovascular disease providers in Ohio

Medicare billing

Part B allowed, 2024
$119,364
Medicare patients
1,033
Services billed
2,136

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban66$56,867
EntrestoSacubitril/Valsartan11$21,473
Colchicine18$1,464
Metoprolol Succinate112$1,430
Ranolazine ErRanolazine16$659
Rosuvastatin Calcium64$550
Torsemide28$510
Losartan Potassium58$477
Atorvastatin Calcium55$358
Spironolactone24$270
Carvedilol31$237
Lisinopril39$110
Amiodarone Hcl14$99
ClopidogrelClopidogrel Bisulfate27$69
Metoprolol Tartrate13$69

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$175$56,86766 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 827 cardiovascular disease providers in Ohio.

Other cardiovascular disease in Cleveland

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →